Ratings Oscar Health, Inc.

Equities

OSCR

US6877931096

Real-time Estimate Cboe BZX Other stock markets 03:08:30 2024-06-06 pm EDT			5-day change	1st Jan Change
19.3 ^USD	-2.01%		-3.93%	+108.42%

May. 30	Oscar Health Upside Overshadowed By Election, Affordable Care Act Uncertainty, BofA Says	MT
May. 30	BofA Securities Downgrades Oscar Health to Neutral From Buy, Adjusts Price Target to $21 From $25	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company is in a robust financial situation considering its net cash and margin position.
The stock, which is currently worth 2024 to 0.3 times its sales, is clearly overvalued in comparison with peers.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
With an expected P/E ratio at 303.08 and 36.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Life & Health Insurance

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OSCAR HEALTH, INC.	+108.85%	4.67B		-
BUPA ARABIA FOR COOPERATIVE INSURANCE COMPANY	+5.15%	9.15B		B-
MEDIBANK PRIVATE LIMITED	+6.18%	6.8B		C+
THE COMPANY FOR COOPERATIVE INSURANCE	+4.15%	5.51B		C
NIB HOLDINGS LIMITED	+2.03%	2.4B		B+
TRUPANION, INC.	-6.52%	1.21B		C
RELIGARE ENTERPRISES LIMITED	+1.88%	842M	-	D+
THE MEDITERRANEAN AND GULF COOPERATIVE INSURANCE AND REINSURANCE COMPANY	+88.89%	770M	-	C
AMANA COOPERATIVE INSURANCE COMPANY	-9.17%	138M	-	-
PT LIPPO GENERAL INSURANCE TBK	-23.46%	57.06M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes